© 2020 MJH Life Sciences and Urology Times. All rights reserved.
© 2020 MJH Life Sciences™ and Urology Times. All rights reserved.
November 27, 2020
"Despite some heterogeneity in the type and frequency of testing during the surveillance period, these results provide reassurance and increased confidence in the safe utilization of AS protocols for men with low-risk GG1, and selected GG2, prostate cancer," Mian writes.
November 25, 2020
At a median follow-up of 15 years, the pooled analysis showed statistically significant improvements with adjuvant ADT over neoadjuvant ADT in biochemical failure, distant metastasis, and progression-free survival rates.
The vaccine RV001 targets RhoC, a small GTPase that is overexpressed in advanced solid tumors.
November 16, 2020
SpaceOAR Vue Hydrogel, a radiopaque perirectal spacer for radiation therapy, is now available in the United States for use in patients with prostate cancer receiving radiotherapy.
November 13, 2020
"If your practice does not closely monitor patients and send them for early salvage radiotherapy when their PSA is 0.1 or 0.2 ng/mL, it is likely that adjuvant radiotherapy is superior," Daniel E. Spratt, MD, writes.
Christopher P. Evans, MD, and J. Brantley Thrasher, MD, conclude an in-depth discussion on active surveillance in men with low-risk prostate cancer.
November 12, 2020
In this video, Samuel J. Peretsman, MD, also discusses his experience with robotic prostatectomy following HIFU.
November 11, 2020
Christopher P. Evans, MD, discusses his active surveillance protocol with J. Brantley Thrasher, MD.
November 09, 2020
FoundationOneLiquid CDx will identify HRR alterations, such as BRCA1, BRCA2, and ATM, that make a patient eligible for olaparib.
November 06, 2020
“Metastatic prostate cancer is a complex cancer with marked inter- and intrapatient heterogeneity; therapy development must focus on the totality of disease biology,” said Maha Hussain, MD.